Table 3. Distribution of studied patients according to the allergic reaction to taken biological therapy, clinical and laboratory data, and drugs used.
Anti-CCP; anti-cyclic citrullinated peptide, Anti-MCV; anti-mutated citrullinated vimentin, ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, dsDNA; double-stranded DNA, ANA; antinuclear antibodies, DAS-28; disease activity score, AST; aspartate aminotransferase, ALT; alanine transaminase, NSAIDs; nonsteroidal anti-inflammatory drugs, HB level; hemoglobin level, MTX dose; methotrexate dose, ASA; acetylsalicylic acid
| Variable | No. (%) | |
| Allergic reaction to taken biological therapy | Yes | 31 (9.3) |
| No | 304 (90.7) | |
| If yes, what is the allergic drug? | Rituximab | 13 (41.9) |
| Infliximab | 6 (19.4) | |
| Adalimumab (Humira) | 4 (12.9) | |
| Etanercept (Enbrel) | 4 (12.9) | |
| Tocilizumab | 4 (12.9) | |
| Anti-CCP | Yes | 166 (49.6) |
| No | 169 (50.4) | |
| Anti-MCV | Yes | 193 (57.6) |
| No | 141 (42.1) | |
| Not applicable | 1 (0.3) | |
| ESR | High | 172 (51.3) |
| Normal | 163 (48.7) | |
| CRP | >3 | 236 (70.4) |
| ≤ 3 | 98 (29.3) | |
| Not applicable | 1 (0.3) | |
| dsDNA | 0-200 | 41.5 (31.4) |
| 201-300 | 30.1 (30.1) | |
| 301-800 | 26.9 (26.9) | |
| >800 | 1.5 (1.5) | |
| ANA | Positive | 201 (60) |
| Negative | 134 (40) | |
| Activity | Yes | 280 (83.6) |
| No | 55 (16.4) | |
| DAS-28 | ≤ 2.6 | 2 (0.6) |
| 2.6-3.2 | 114 (34) | |
| 3.2-5.1 | 163 (48.7) | |
| ≥ 5.1 | 56 (16.7) | |
| ≤ 2.6 | 2 (0.6) | |
| AST | <10 | 93 (27.8) |
| 10-40 | 156 (46.6) | |
| >40 | 86 (25.7) | |
| ALT | <7 | 93(27.8) |
| 7-56 | 164 (49) | |
| >56 | 78 (23.3) | |
| ASA | Yes | 65 (19.4) |
| No | 270 (80.6) | |
| NSAIDs | Yes | 270 (80.6) |
| No | 65 (19.4) | |
| Steroid dose | <5mg | 190 (56.7) |
| 5-10mg | 133 (39.7) | |
| >10mg | 12 (3.6) | |
| Used drugs | Methotrexate | 263 (78.5) |
| Antimalarial | 107 (31.9) | |
| Methtrx | 268 (80) | |
| Sulfa | 60 (17.9) | |
| Avara | 49 (14.6) | |
| Immurane | 47 (14) | |
| Mean and SD of study variables | Disease duration (months) | 38.91 ± 70.16 |
| HB level | 11.78 ± 1.73 | |
| Platelet level | 324.24 ± 100.71 | |
| Creatine level | 88.65 ± 389.67 | |
| MTX dose | 8.68± 4.41 | |